Sustained response to atogepant in individuals with episodic migraine and prior inadequate response to preventive treatment and in individuals with chronic migraine: post-hoc analyses from ELEVATE and PROGRESS

被引：0
|
作者：
Lipton, R. B. [1 ]
Chalermpalanupap, N. [2 ]
Tatsuoka, Y. [3 ]
Nagy, K. [4 ]
Liu, Y. [5 ]
Carr, K. [5 ]
McAllister, P. [6 ]
Nahas, S. J. [7 ]
Trugman, J. M. [2 ]
Sacco, S. [8 ]
机构：
[1] Albert Einstein Coll Med, Bronx, MA USA
[2] AbbVie, Madison, NJ USA
[3] Tatsuoka Neurol Clin, Kyoto, Japan
[4] AbbVie, Budapest, Hungary
[5] AbbVie, N Chicago, IL USA
[6] New England Inst Neurol & Headache, Stamford, CT USA
[7] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA
[8] Univ Aquila, Laquila, Italy
来源：
JOURNAL OF HEADACHE AND PAIN | 2024年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P036
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Sustained and Subsequent Response to Atogepant Among Individuals With Episodic Migraine With Prior Treatment Failure: Post Hoc Analysis of the ELEVATE Trial
    Sacco, Simona
    Nagy, Krisztian
    Chalermpalanupap, Natty
    Vernieri, Fabrizio
    Smith, Jonathan H.
    Holle-Lee, Dagny
    Liu, Yingyi
    Carr, Karen
    Pozo-Rosich, Patricia
    Lipton, Richard B.
    CEPHALALGIA, 2023, 43 (1supp) : 265 - 266
  • [2] Sustained and Subsequent Response to Atogepant Among Individuals With Chronic Migraine: Post Hoc Analysis of the PROGRESS Trial
    Lipton, R.
    Chalermpalanupap, N.
    Nahas-Geiger, S.
    Pozo-Rosich, P.
    McAllister, P.
    Tatsuoka, Y.
    Liu, Y.
    Dabruzzo, B.
    Smith, J.
    Bilchik, T.
    HEADACHE, 2023, 63 : 168 - 169
  • [3] Subsequent response to atogepant in individuals with episodic migraine after an initial inadequate response: Post hoc analyses of a 12-week phase 3 trial
    Dodick, D. W.
    Nahas, S. J.
    Pozo-Rosich, P.
    Bilchik, T. R.
    McAllister, P.
    Finnegan, M.
    Ma, J.
    Chalermpalanupap, T.
    Dabruzzo, B. L.
    Lipton, R. B.
    HEADACHE, 2022, 62 : 164 - 165
  • [4] Sustained Response to Atogepant in Individuals with Episodic Migraine: Post Hoc Analyses of 12-and 52-Week Phase 3 Trials
    Lipton, R.
    Nahas, S.
    Pozo-Rosich, P.
    Bilchik, T.
    McAllister, P.
    Finnegan, M.
    Ma, J.
    Chalermpalanupap, T.
    Dabruzzo, B.
    Dodick, D.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [5] Sustained response to atogepant in individuals with episodic migraine: Post hoc analyses of 12-and 52-week phase 3 trials
    Lipton, R. B.
    Nahas, S. J.
    Pozo-Rosich, P.
    Bilchik, T. R.
    McAllister, P.
    Finnegan, M.
    Ma, J.
    Chalermpalanupap, T.
    Dabruzzo, B. L.
    Dodick, D. W.
    HEADACHE, 2022, 62 : 165 - 166
  • [6] Atogepant for the Preventive Treatment of Migraine Among Participants With Episodic Migraine With Prior Treatment Failure: Results From the ELEVATE Trial
    Pozo-Rosich, P.
    Nagy, K.
    Tassorelli, C.
    Lanteri-Minet, M.
    Sacco, S.
    Nezadal, T.
    Finnegan, M.
    Guo, H.
    Ferreira, De Abreu R.
    Trugman, J.
    HEADACHE, 2023, 63 : 117 - 117
  • [7] Atogepant for the Preventive Treatment of Migraine Among Participants With Episodic Migraine With Prior Treatment Failure: Results From the ELEVATE Trial
    Pozo-Rosich, Patricia
    Nagy, Krisztian
    Tassorelli, Cristina
    Lanteri-Minet, Michel
    Sacco, Sara
    Nezadal, Tomas
    Finnegan, Michelle
    Guo, Hua
    Ferreira, Rosa De Abreu
    Trugman, Joel M.
    CEPHALALGIA, 2023, 43 (1supp) : 47 - 49
  • [8] Atogepant demonstrates early functional and quality of life improvements for the preventive treatment of episodic migraine after prior inadequate response to treatment: results from the ELEVATE trial
    Holle-Lee, D.
    Gandhi, P.
    Reuter, U.
    Ailani, J.
    Lipton, R. B.
    Nagy, K.
    Liu, Y.
    Carr, K.
    Stokes, J.
    Tassorelli, C.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [9] Subsequent Response to Atogepant in Individuals with Episodic Migraine after an Initial Inadequate Response: Post Hoc Analysis of a 12-week Phase 3 Trial
    Dodick, D.
    Nahas, S.
    Pozo-Rosich, P.
    Bilchik, T.
    McAllister, P.
    Finnegan, M.
    Ma, J.
    Chalermpalanupap, T.
    Dabruzzo, B.
    Lipton, R.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [10] Benefit-Risk assessment of atogepant vs. placebo in participants with episodic migraine who had prior inadequate response to 2-4 classes of oral preventive treatment: a post-hoc analysis of the ELEVATE trial
    Reuter, U.
    Lalla, A.
    Sacco, S.
    Holle-Lee, D.
    Pozo-Rosich, P.
    Nagy, K.
    Luo, L.
    Carr, K.
    Gandhi, P.
    Tassorelli, C.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
12345